Halozyme Therapeutics (NASDAQ:HALO) Upgraded to Strong-Buy at Wall Street Zen

Key Points

• Analyst sentiment improved: Wall Street Zen upgraded Halozyme Therapeutics to “strong buy,” while several firms raised price targets to $105–$115. The broader consensus remains “Moderate Buy,” with a $91.20 average target.
• Quarterly results exceeded expectations: Halozyme reported $2.28 in EPS and $481 million in revenue, beating estimates by $0.49 per share and roughly $79 million, respectively. Revenue increased 47.7% year over year.
• Management raised 2026 guidance: The company now expects non-GAAP EPS of $8.65–$9.00, supported by strong royalty growth and five new ENHANZE and Hypercon agreements signed year to date. Shares opened at $103.12, near their 52-week high of $103.30.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday.

Other research analysts also recently issued reports about the stock. TD Cowen increased their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research report on Friday. Weiss Ratings raised Halozyme Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 31st. HC Wainwright lifted their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a "buy" rating in a research report on Friday. Morgan Stanley reduced their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a report on Tuesday, May 12th. Finally, Wells Fargo & Company upped their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Friday. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $91.20.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $103.12 on Friday. The stock has a 50 day moving average price of $76.48 and a 200 day moving average price of $71.47. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81. The company has a market capitalization of $12.23 billion, a price-to-earnings ratio of 30.78, a price-to-earnings-growth ratio of 0.36 and a beta of 0.85. Halozyme Therapeutics has a 52-week low of $61.22 and a 52-week high of $103.30.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 232.11%. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period in the prior year, the firm posted $1.54 earnings per share. The firm's revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts predict that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Mahesh Krishnan sold 7,304 shares of the firm's stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director owned 14,462 shares of the company's stock, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $51,886,572.40. This represents a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 72,477 shares of company stock valued at $5,102,643. Insiders own 2.50% of the company's stock.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Empowered Funds LLC purchased a new stake in shares of Halozyme Therapeutics during the first quarter worth approximately $755,000. Acadian Asset Management LLC acquired a new position in Halozyme Therapeutics in the 1st quarter valued at $195,000. Hsbc Holdings PLC raised its position in Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company's stock worth $522,000 after buying an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock worth $140,000 after acquiring an additional 174 shares during the period. Finally, Baird Financial Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 6.2% in the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company's stock valued at $577,000 after acquiring an additional 650 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source